SAB Biotherapeutics (SABS) Invested Capital (2021 - 2023)

SAB Biotherapeutics' (SABS) quarterly Invested Capital came in at $3.6 million in Q2 2023, down 3.12% on a QoQ basis from $3.7 million in Q1 2023.

SAB Biotherapeutics (SABS) Invested Capital (2021 - 2023) Analysis & Trends

SAB Biotherapeutics (SABS) has 3 years of Invested Capital data on file, last reported at $3.6 million in Q2 2023.

Quarterly Invested Capital changed N/A year-over-year to $3.6 million in Q2 2023, while the trailing twelve-month figure through Mar 2024 was $3.6 million (down 51.77% YoY) and the FY2022 annual result came in at $3.8 million, down 4.1% from the prior year.
Invested Capital declined to $3.6 million in Q2 2023, from $3.7 million in the prior quarter.
In the past five years, Invested Capital ranged from a high of $3.9 million in Q4 2021 to a low of $3.6 million in Q2 2023.
A 3-year average of $3.8 million and a median of $3.7 million in 2022 frame the typical range for Invested Capital.
The widest YoY moves for Invested Capital: up 4.1% in 2022, down 4.1% in 2022.
Tracing SABS's Invested Capital over 3 years: stood at $3.9 million in 2021, then slipped by 4.1% to $3.8 million in 2022, then dropped by 3.98% to $3.6 million in 2023.
The last three Invested Capital figures came in at $3.6 million (Q2 2023), $3.7 million (Q1 2023), and $3.8 million (Q4 2022), per Business Quant data.

#	Company	Market Cap	Enterprise Value	Gross Profit (Qtr)	Invested Cap. (Qtr)
1	Vertex Pharmaceuticals	128.13 Bn	120.28 Bn	2.84 Bn	-
2	Regeneron Pharmaceuticals	112.33 Bn	104.33 Bn	3.93 Bn	-
3	Argenx Se	53.24 Bn	48.05 Bn	1.41 Bn	-
4	Revolution Medicines	43.64 Bn	43.64 Bn	-	-
5	BeOne Medicines	39.27 Bn	34.17 Bn	1.53 Bn	190.90 Mn
6	MindWalk Holdings	35.32 Bn	35.31 Bn	1.82 Bn	2.57 Mn
7	Royalty Pharma	33.72 Bn	35.84 Bn	-	380.00 Mn
8	Alnylam Pharmaceuticals	30.58 Bn	27.27 Bn	992.69 Mn	-
9	Insmed	27.01 Bn	25.85 Bn	358.27 Mn	-
10	SAB Biotherapeutics	308.92 Mn	308.92 Mn	-	-

Download Data